D228

D228 is an orally active antiinflammatory agent. D228 reduces ConA induced T lymphocyte cell proliferation (IC50: 42.85 μM) and LPS induced B lymphocyte cell proliferation (IC50: 3.15 μM) . D228 is effective against inflammatory bowel disease (IBD) . D228 alleviates the DSS (HY-116282C) -induced inflammation response in the IBD model by downregulating the MyD88/TRAF6/p38 signaling[1].

Product Specifications

CAS Number

[2676188-98-8]

UNSPSC

12352005

Target

MyD88; p38 MAPK

Type

Reference compound

Related Pathways

Immunology/Inflammation; MAPK/ERK Pathway

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/d228.html

Purity

99.77

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

CC1=C(C(/C(O1)=C(C)\C)=O)O[C@H]2[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O2

Molecular Formula

C22H28O12

Molecular Weight

484.45

References & Citations

[1]Tang ML, et al. From Hit to Lead: Discovery of First-In-Class Furanone Glycoside D228 Derived from Chimonanthus salicifolius for the Treatment of Inflammatory Bowel Disease. J Med Chem. 2024 Oct 10;67 (19) :17101-17123.